<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876796</url>
  </required_header>
  <id_info>
    <org_study_id>0976-103</org_study_id>
    <nct_id>NCT02876796</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Pharmacodynamic Effects of A Single Oral Dose of NDI-010976 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nimbus Apollo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976
      (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose
      administration in overweight and/or obese, but otherwise healthy, male adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fractional DNL (% new palmitate)</measure>
    <time_frame>Predose and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in DNL over time following administration of GS-0976 and placebo</measure>
    <time_frame>Predose and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline over time in adiponectin</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline over time in adiponectin</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline over time in leptin</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline over time in leptin</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline over time in blood ketones</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline over time in blood ketones</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline over time in lipid profile</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline over time in lipid profile</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of treatment-emergent adverse events (TEAEs) following single oral doses of GS-0976 and placebo</measure>
    <time_frame>Up to 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing abnormal clinical laboratory tests</measure>
    <time_frame>Up to 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of GS-0976 and its metabolite: tmax</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of GS-0976 and its metabolite: Cmax</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of GS-0976 and its metabolite: AUC_0-t</measure>
    <time_frame>Baseline and up to 10 hours postdose</time_frame>
    <description>AUC_0-t is defined as the concentration of drug over time from time zero to time &quot;t&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>PD Effects of GS-0976 (NDI-010976) on Fractional DNL</condition>
  <arm_group>
    <arm_group_label>50 mg GS-0976 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1:
Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
Sequence 2:
Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3:
Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
Sequence 4:
Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg GS-0976 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 5:
Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
Sequence 6:
Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-0976</intervention_name>
    <description>Capsule(s) administered orally</description>
    <arm_group_label>50 mg GS-0976 (Cohort 1)</arm_group_label>
    <arm_group_label>200 mg GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_label>20 mg GS-0976 (Cohort 3)</arm_group_label>
    <other_name>NDI-010976</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule(s) administered orally</description>
    <arm_group_label>50 mg GS-0976 (Cohort 1)</arm_group_label>
    <arm_group_label>200 mg GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_label>20 mg GS-0976 (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-13C acetate</intervention_name>
    <description>10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours</description>
    <arm_group_label>50 mg GS-0976 (Cohort 1)</arm_group_label>
    <arm_group_label>200 mg GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_label>20 mg GS-0976 (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructose solution</intervention_name>
    <description>Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses</description>
    <arm_group_label>50 mg GS-0976 (Cohort 1)</arm_group_label>
    <arm_group_label>200 mg GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_label>20 mg GS-0976 (Cohort 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight and/or obese, but otherwise healthy males

          -  Weight ≥ 50.0 kg

          -  Body Mass Index (BMI): 25.0 - 32.0 kg/m^2, inclusive

        Exclusion Criteria:

          -  Intolerance to or malabsorption of fructose

          -  A history of clinically significant gastrointestinal disease and/or surgery, which
             would result in the subject's inability to absorb or metabolize the study drug (e.g.,
             gastrectomy, gastric bypass, cholecystectomy).

          -  In the opinion of the Investigator, a history of clinically significant hematologic,
             renal, hepatic, bronchopulmonary, neurological, psychiatric, metabolic , endocrine
             disorder (e.g., diabetes, thyroid disease), or cardiovascular disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Myers, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fractional de novo lipogenesis</keyword>
  <keyword>DNL</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

